Law and professional code

Undesirable Medical Advertisements Ordinance (Cap. 231)

Under section 3 of the Undesirable Medical Advertisements Ordinance (Cap. 231), a person must not publish or cause to be published an advertisement likely to lead to the use of any medicine, surgical appliance or treatment for treating or preventing a disease specified in the Schedule. The Schedule includes any organic condition affecting sight (advertising is permitted only for locally applied eye preparations to relieve symptoms) and endocrine disease (including diabetes). This education website only covers recognising symptoms, when to seek care, and classes of options a doctor may discuss. It does not promote a named product and does not promise effect, cure or preservation of sight.

Pharmacy and Poisons Ordinance (Cap. 138)

Under the Pharmacy and Poisons Ordinance (Cap. 138) and related regulations, a pharmaceutical product generally must be registered with the Pharmacy and Poisons Board before it may be sold, offered for sale or distributed. Prescription medicines (including most eye drops, ointments and all intravitreal injections) must not be self-purchased. Import or use of an unregistered product by an individual patient may be governed by other legal arrangements. Promoting a treatment is also regulated by Cap. 231 and the Medical Council Code. Approval by an overseas regulator does not mean the product is registered or available in Hong Kong.

Medical Council Code of Professional Conduct

This education site does not carry clinic addresses, phone numbers, fees or booking routes, and does not link to any practice website. Authors/reviewers are identified only by name, specialist register field and qualifications. There are no outcome promises, comparisons with other doctors, patient testimonials, or words such as “cure / most effective”.

Diagnosis requires an in-person visit

This content cannot replace an in-person consultation with a registered ophthalmologist and is not a diagnosis. This page is not diagnostic, prescribing or surgical advice. Only doctors listed on the Medical Council specialist register in ophthalmology may use the title “ophthalmologist” (眼科專科醫生).

Review and corrections

Site last reviewed: 6 October 2026 · Dr Poon Ka Kin，Ophthalmologist（Registered doctor, Medical Council of Hong Kong; Specialist Register (Ophthalmology)）。

• 香港中文大學內外全科醫學士 MBChB (CUHK)
• 英國愛丁堡皇家外科醫學院院員 MRCS(Ed)
• 香港眼科醫學院院士 FCOphth HK
• 香港醫學專科學院院士（眼科）FHKAM (Ophthalmology)

Publisher / operator: 護眼學堂 (eyesinfo.org). Clinical review: Dr Poon Ka Kin (registered doctor, Medical Council of Hong Kong; Specialist Register (Ophthalmology)). This education site does not provide clinic contact, booking or referral, and does not link to a practice website. This education site currently has no commercial sponsorship; if funding or conflicts of interest arise later, they will be disclosed on the legal page. Education content is shown separately from any clinic promotion; the reviewer may also practise clinically — this site does not refer.

This site was founded, funded and is operated by Dr Poon Ka Kin.

This site is self-funded by Dr Poon Ka Kin.

If you find a content error, email hokusaivision@gmail.com (For content corrections/suggestions only — not for bookings, clinical advice, or referrals.). The corrections policy is this paragraph. At this stage the site does not receive medical records, bookings or individual care queries.

Selected public references (not a full bibliography)

• Yam JC et al. Low-Concentration Atropine for Myopia Progression (LAMP). Ophthalmology. 2019.（第一年）
• AREDS2 Research Group. JAMA. 2013.
• Azuara-Blanco A et al. EAGLE. Lancet. 2016.
• TFOS DEWS II. Ocul Surf. 2017.
• 香港醫務委員會《專業守則》；《不良廣告（醫藥）條例》（第231章）；《藥劑業及毒藥條例》（第138章）。

Copyright

© 2026 護眼學堂 (eyesinfo.org). Public education. All rights reserved. Reproduce only with the credit “護眼學堂 · eyesinfo.org”. Do not strip the source or reuse or adapt the text as clinic promotion, a booking page, or to sell medicines or surgery. This site does not book or refer.